07:00 , Aug 19, 2013 |  BioCentury  |  Emerging Company Profile

PxRadia: Ceramide selectivity

PxRadia Inc. is developing a mAb that directly targets ceramide molecules in the cell membrane, blocking their ability to induce apoptosis in tissues subjected to stressors such as radiation. But the mAb doesn't impair normal...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Company News

Humanetics other news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Humanetics a two-year, $3.5 million contract for preclinical testing of BIO 300 to prevent lung injury caused by radiation exposure from a nuclear detonation. The radioprotectant...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Clinical News

BIO 300: Phase I data

In an open-label, dose-escalation, U.S. Phase I (MARC006-025) trial in adult volunteers, BIO 300 was well tolerated. The trial evaluated single oral doses of 500, 1,000, 1,500 and 2,000 mg of BIO 300. Humanetics Corp....
08:00 , Jan 7, 2008 |  BioCentury  |  Product Development

ARS fallout

Osiris Therapeutics Inc. hit the jackpot last Friday, winning a $224.7 million contract from the...
07:00 , Jul 30, 2007 |  BC Week In Review  |  Clinical News

BIO 300 regulatory update

FDA granted Orphan Drug designation for BIO 300, an oral radioprotectant, for the prevention of acute radiation syndrome. Humanetics Corp. , Minneapolis, Minn.   Product: BIO 300   Business: Other  ...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Clinical News

BIO 300: Phase I start

Next month, Humanetics will begin a Phase I trial in about 30 healthy volunteers. Humanetics Corp. , Minneapolis, Minn.   Product: BIO 300   Business: Other   Molecular target: NA   Description: Radioprotectant   Indication:...